- Prof. Herman Yeger
- Developmental and Stem Cell Biology, Peter Gilgan Centre for Research and Learning, The Hospital for Sick Children, Toronto, ON, Canada.
Website | E-mail
Special Issue Introduction
Neuroblastoma, a pediatric cancer originating from the embryonal, peripheral nervous system, invested with the highly migratory neural crest anlage, occurs mainly during postnatal and childhood period with a multivariate phenotype. The stem cell properties of the neural crest appear to be retained in the development of neuroblastoma. Neuroblastomas acquire a relatively small number of genomic aberrations and specific gene amplifications (e.g., MYCN) that are associated with malignant progression. Germline mutations in PHOX2B and Alk, and other anomalies, are associated with heritability, malignant stage and progression. However, clinically lower stage variants are mostly amenable to resolution, either by spontaneous regression or by different treatment modalities. Besides, at a relatively high success rate, the highest stage IV neuroblastoma is still seriously problematic, and despite a plethora of small molecule therapeutics, molecular targeting, and newer immunotherapies, overall survival has not significantly exceeded 60%. In this regard, stage IV neuroblastoma manifests a propensity for aggressive metastasis and resistance to treatments.
This special issue on Research Advances on Neuroblastoma in JCMT will explore our current understanding of the origin, the biology of neuroblastoma, disease modeling, the tumor microenvironment, metastasis, current and developing therapeutics, and interactions with the immune system, which could modulate progression, sustain the malignant phenotype of this cancer, and potentially offer novel therapeutic targets. The goal of this special issue is to delve deeper into the biology of neuroblastoma, uncover innovative therapeutic approaches, and identify new avenues for tackling this clinically challenging cancer. Authors are invited to submit manuscripts on original laboratory studies, reviews, perspectives, and technical advances that may illuminate the objectives of this special issue. This special issue presents an opportunity for young investigators to present any of their studies for peer review and recognition. It is expected that this special issue will also serve as a forum for introducing readers to early career investigators, and for stimulating collaborations amongst investigators in the neuroblastoma and related fields.
Neuroblastoma, developmental biology, molecular biology, malignant progression, disease modeling, therapeutic modalities
Submission Deadline28 Feb 2022